Eledon Pharmaceuticals, Inc. Common Stock ELDN

$3.45 -1.99% at last close

Analyst Consensus

Consensus Rating
Buy (3 Buy · 0 Hold · 0 Sell)
Average Price Target
$9.67
Implied Upside
+180.2%
Price Target Range
$8.00 – $12.00
Analysts (12 mo)
3

Recent Analyst Actions

DateFirmActionRatingPrice Target
2026-07-21
Rodman & RenshawSeema Sheoran
Initiates coverage on Buy $12
2025-11-18
GuggenheimVamil Divan
Maintains Buy $9 → $8
2025-09-02
HC Wainwright & Co.Yi Chen
Reiterates Buy $9
2025-07-25
Craig-Hallum
Initiates coverage on Buy $12
2025-06-18
HC Wainwright & Co.Yi Chen
Assumes Buy $9
2024-11-20
HC Wainwright & Co.Vernon Bernardino
Reiterates Buy $16
2024-06-04
HC Wainwright & Co.Vernon Bernardino
Reiterates Buy $16
2024-05-10
HC Wainwright & Co.Vernon Bernardino
Reiterates Buy $16
2024-05-07
HC Wainwright & Co.Vernon Bernardino
Maintains Buy $13 → $16
2024-03-22
HC Wainwright & Co.Vernon Bernardino
Reiterates Buy $13
2023-11-13
HC Wainwright & Co.Vernon Bernardino
Reiterates Buy $13
2023-10-24
HC Wainwright & Co.Vernon Bernardino
Maintains Buy $25 → $13
2023-09-27
Noble Capital MarketsRobert LeBoyer
Initiates coverage on Outperform $10
2023-08-22
Cantor FitzgeraldAlethia Young
Reiterates Overweight $9
2023-05-26
HC Wainwright & Co.Vernon Bernardino
Reiterates Buy $25
2022-06-01
SVB LeerinkThomas Smith
Maintains Outperform $33 → $26
2021-11-24
HC Wainwright & Co.Vernon Bernardino
Maintains Buy $35 → $25
2021-04-27
SVB LeerinkThomas Smith
Maintains Outperform $34 → $33
2021-03-23
Cantor FitzgeraldAlethia Young
Initiates coverage on Overweight $25
2021-02-08
SVB LeerinkThomas Smith
Initiates coverage on Outperform $34

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$3.45
Market Cap
$286.04 million
52-Week Range
$1.35 $4.60
Average Volume
932K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.